نتائج البحث - "Shengyan Hong"

1

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Rugo, H. S., Im, S. -A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escriva-De-Romani, S., De Laurentiis, M., Levy, C., Brown-Glaberman, U., Ferrero, J. -M., De Boer, M., Kim, S. -B., Petrakova, K., Yardley, D. A., Freedman, O., Jakobsen, E. H., Kaufman, B., Yerushalmi, R., Fasching, P. A., Nordstrom, J. L., Bonvini, E., Koenig, S., Edlich, S., Hong, S., Rock, E. P., Gradishar, W. J., Institut Català de la Salut, [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center. [Im SA] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. [Cardoso F] Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal. [Cortés J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: SOPHIA Study Group 2021, ' Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer : A Phase 3 Randomized Clinical Trial ', JAMA Oncology, vol. 7, no. 4, pp. 573-584 . https://doi.org/10.1001/jamaoncol.2020.7932Test
JAMA Oncology, 7(4), 573-584. American Medical Association
JAMA Oncol
Scientia

مصطلحات موضوعية: Oncology, Relative risk reduction, Cancer Research, MONOCLONAL-ANTIBODY, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Ado-Trastuzumab Emtansine, RECOMMENDATIONS, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Original Investigation, Aged, 80 and over, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], benefit, Hazard ratio, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Antibodies, Monoclonal, Middle Aged, CHEMOTHERAPY, Chemotherapy regimen, 030220 oncology & carcinogenesis, Female, Pertuzumab, medicine.drug, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, IMMUNITY, survival, Quimioteràpia combinada, 03 medical and health sciences, Breast cancer, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, medicine, Humans, Aged, C RECEPTOR POLYMORPHISMS, therapy, business.industry, association, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Interim analysis, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beae17ac62d0e63c250dbce6359002edTest
https://doi.org/10.1001/jamaoncol.2020.7932Test

2

Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer

المصدر: Cancer Research. 81:PS10-24

مصطلحات موضوعية: Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, Nausea, medicine.medical_treatment, Vinorelbine, Gastroenterology, Loading dose, Gemcitabine, Oncology, Tolerability, Internal medicine, parasitic diseases, medicine, population characteristics, Chills, Premedication, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ca44da885a57e29a600f1ae9727193d2Test
https://doi.org/10.1158/1538-7445.sabcs20-ps10-24Test

3

مؤتمر

المساهمون: Javier Cortes,1 Fatima Cardoso, Giuseppe Curigliano, William J Gradishar, Seock-Ah Im, Hope S Rugo, Shakeela W Bahadur, Alfredo Falcone, Serafin Morales Murillo, David A Riseberg, Antonino Musolino, Trevor M Feinstein, Miguel H Abreu, Young-Hyuck Im, Yelena Novik, Timothy Pluard, Lupe G Salazar, Rossana Berardi, Viorela Pop, Shengyan Hong Kenneth Jacobs, Edwin Rock and Mark D Pegram, Cortes, Javier, Cardoso, Fatima, Curigliano, Giuseppe, J Gradishar, William, Im, Seock-Ah, S Rugo, Hope, W Bahadur, Shakeela, Falcone, Alfredo, Morales Murillo, Serafin, A Riseberg, David, Musolino, Antonino, M Feinstein, Trevor, H Abreu, Miguel, Im, Young-Hyuck, Novik, Yelena, Pluard, Timothy, G Salazar, Lupe, Berardi, Rossana, Pop, Viorela, Hong, Shengyan, Jacobs, Kenneth, D Pegram, Edwin Rock and Mark

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000618737700286; ispartofbook:Infusion-Related Reactions in the Phase 3 SOPHIA Trial of Margetuximab + Chemotherapy vs Trastuzumab + Chemotherapy in Patients With Pretreated HER2+ Metastatic Breast Cancer; San Antonio Breast Cancer Symposium (SABCS); http://hdl.handle.net/11566/285983Test

الإتاحة: http://hdl.handle.net/11566/285983Test

View record in BASE